Results 1 to 10 of about 23,433 (227)

Association between serum osteoprotegerin level and renal prognosis in nondialysis patients with chronic kidney disease in the Korean Cohort Study for Outcomes in Patients with Chronic Kidney Disease (the KNOW-CKD Study) [PDF]

Kidney Research and Clinical Practice, 2022
Background Osteoprotegerin is an important regulator of bone metabolism and vascular calcification. The association between serum osteoprotegerin level and chronic kidney disease (CKD) progression has not been elucidated.
Tae Ryom Oh, Chana Myeong, Su Hyun Song, Hong Sang Choi, Sang Heon Suh, Chang Seong Kim, Eun Hui Bae, Wookyung Chung, Kyu Hun Choi, Kook Hwan Oh, Seong Kwon Ma, Soo Wan Kim   +11 more
doaj   +1 more source

Angiotensin II Induces Aortic Rupture and Dissection in Osteoprotegerin‐Deficient Mice

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2022
Background The biological mechanism of action for osteoprotegerin, a soluble decoy receptor for the receptor activator of nuclear factor‐kappa B ligand in the vascular structure, has not been elucidated.
Toshihiro Tsuruda, Atsushi Yamashita, Misa Otsu, Masanori Koide, Yuko Nakamichi, Yoko Sekita‐Hatakeyama, Kinta Hatakeyama, Taro Funamoto, Etsuo Chosa, Yujiro Asada, Nobuyuki Udagawa, Johji Kato, Kazuo Kitamura   +12 more
doaj   +1 more source

Effect of sequential eradication therapy on serum osteoprotegerin levels in patients with infection and co-existing inflammatory bowel disease

Journal of International Medical Research, 2021
Objective To investigate the effect of sequential Helicobacter pylori eradication therapy on serum osteoprotegerin levels in patients with H. pylori infection and co-existing inflammatory bowel disease (IBD).
Hussam Murad, Misbahuddin Rafeeq, Mahmoud Mosli, Mamdouh Gari, Mohammed Basheikh   +4 more
doaj   +1 more source

Osteoprotegerin in Cardiometabolic Disorders [PDF]

International Journal of Endocrinology, 2015
Osteoprotegerin (OPG), a glycoprotein traditionally implicated in bone remodelling, has been recently related to cardiovascular disease (CVD). Human studies show a positive relationship between circulating OPG, vascular damage, and CVD, and as such OPG has emerged as a potential biomarker for CVD.
Pérez de Ciriza, C., Lawrie, A., Varo, N.   +2 more
openaire   +6 more sources

Association of Serum Osteoprotegerin Level With Myocardial Injury and Cardiovascular Calcification in Chronic Kidney Disease Patients

Frontiers in Medicine, 2022
BackgroundChronic kidney disease has emerged as a significant independent risk factor for cardiovascular disease. Cardiovascular calcification is an active process involving a complex interaction of inducers and inhibitors.
Kamal M. Okasha, Mohamed Hussein Aboufreikha, Waleed Elrefaey, Medhat M. Ashmawy, Heba Mourad, Mohamed A. Elsebaey, Mohammed H. Elnaggar, Raghda Gabr Mashaal, Sama Metwally, Shaimaa Samir Amin Mashal, Neveen A. Shalaby, Shireen Ali Elhoseny, Amr Alkassas, Mohammed Elbarbary, Osama Shoeib, Dina A. Ali, Nivin Baiomy, Sherein M. Alnabawy   +17 more
doaj   +1 more source

SYNOVIAL AND SERUM LEVELS OF OSTEOCALCIN, OSTEOPROTEGERIN AND Β-CROSSLAPS IN PATIENTS WITH CALCIUM PYROPHOSPHATE DEPOSITION DISEASE [PDF]

Romanian Journal of Rheumatology, 2019
Background. Calcium pyrophosphate deposition disease is defined by deposition of calcium pyrophosphate crystals in hyaline cartilage, fibrocartilage and soft tissues. The study of bone markers is of great interest in different types of arthritis.
Paulina Vele, Ciprian N. Silaghi, Laura O. Damian, Siao-Pin Simon, Alexandra M. Craciun, Simona Rednic   +5 more
doaj   +1 more source

Osteoprotegerin Prevents Intracranial Aneurysm Progression by Promoting Collagen Biosynthesis and Vascular Smooth Muscle Cell Proliferation

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2020
Background Decreased extracellular matrix formation and few vascular smooth muscle cells (VSMCs) in cerebral vascular walls are the main characteristics of intracranial aneurysm (IA) pathogenesis.
Takeshi Miyata, Manabu Minami, Hiroharu Kataoka, Kosuke Hayashi, Taichi Ikedo, Tao Yang, Yu Yamamoto, Masayuki Yokode, Susumu Miyamoto   +8 more
doaj   +1 more source

OSTEOPROTEGERIN, RANK, RANKL [PDF]

Biomedical Papers, 2001
Osteoprotegerin, RANK (Receptor Activator of Nuclear factor kappa B) and RANKL (Receptor Activator of Nuclear faktor kappa B ligand) became the aim of intensive research. RANK is considered as a hematopoietic surface receptor controlling osteoclastogenesis and calcium metabolism.
D, Stejskal, J, Bartek, R, Pastorková, V, Růzicka, I, Oral, D, Horalík   +5 more
openaire   +2 more sources

Value of osteoprotegerin, RANKL, interleukin-17 in mechanisms of bone metabolism disorders

Journal of Education, Health and Sport, 2017
The relationship between osteoprotegerin, RANKL and interleukin-17 inthe mechanisms of abnormal remodeling of bone tissue during experimental periodontitis was studied in this work. Increased levels of RANKL and pro-inflammatory IL-17 were found, as well
V. F. Cheremisina
doaj   +3 more sources

Osteoprotegerin concentration and risk of cardiovascular outcomes in nine general population studies: Literature-based meta-analysis involving 26,442 participants. [PDF]

PLoS ONE, 2017
Recent experimental and epidemiological studies have suggested that osteoprotegerin, a key regulator in bone metabolism, may be involved in vascular calcification and atherosclerosis.
Lena Tschiderer, Johann Willeit, Georg Schett, Stefan Kiechl, Peter Willeit   +4 more
doaj   +1 more source